Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Total Liabilities (2016 - 2025)

Integra Lifesciences Holdings (IART) has disclosed Total Liabilities for 17 consecutive years, with $2.6 billion as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 2.66% to $2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.6 billion through Dec 2025, up 2.66% year-over-year, with the annual reading at $2.6 billion for FY2025, 2.66% up from the prior year.
  • Total Liabilities hit $2.6 billion in Q4 2025 for Integra Lifesciences Holdings, down from $2.6 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $2.6 billion in Q2 2025 to a low of $2.1 billion in Q1 2022.
  • Historically, Total Liabilities has averaged $2.3 billion across 5 years, with a median of $2.2 billion in 2023.
  • Biggest five-year swings in Total Liabilities: dropped 7.03% in 2022 and later grew 21.29% in 2024.
  • Year by year, Total Liabilities stood at $2.1 billion in 2021, then fell by 0.58% to $2.1 billion in 2022, then grew by 5.21% to $2.2 billion in 2023, then grew by 13.58% to $2.5 billion in 2024, then grew by 2.66% to $2.6 billion in 2025.
  • Business Quant data shows Total Liabilities for IART at $2.6 billion in Q4 2025, $2.6 billion in Q3 2025, and $2.6 billion in Q2 2025.